ERBB3 Knockout Cell Lysate

ObjectivesPeripheral nerve injuries are a common occurrence, resulting in considerable patient suffering; it also represents a major economic burden on society. To improve treatment options following peripheral nerve injuries, scientists aim to find a way to promote Schwann cell (SC) myelination to help nerves to carry out their functions effectively. In this study, we investigated myelination ability of SCs, regulated by co-culture with adipose-derived stem cells (ASCs) or low-intensity pulsed ultrasound (LIPUS), and synergistic effects of combined treatments. Materials and methodsSchwann cells were co-cultured with or without ASCs, and either left untreated or treated with LIPUS for 10min/d for 1, 4 or 7days. Effects of LIPUS and ASC co-culture on pro-myelination indicators of SCs were analysed by real-time PCR (RT-PCR), Western blotting and immunofluorescence staining (IF). ResultsOur results indicate that ASC-SC co-culture and LIPUS, together or individually, promoted mRNA levels of epidermal growth factor receptor 3 (EGFR3/ErbB3), neuregulin1 (NRG1), early growth response protein 2 (Egr2/Krox20) and myelin basic protein (MBP), with corresponding increases in protein levels of ErbB3, NRG1 and Krox20. Interestingly, combination of ASC-SC co-culture and LIPUS displayed the most remarkable effects. ConclusionWe demonstrated that ASCs upregulated pro-myelination indicators of SCs by indirect contact (through co-culture) and that effects could be potentiated by LIPUS. We conclude that LIPUS, as a mechanical stress, may have potential in nerve regeneration with potential clinical relevance.

HNF4 alpha (hepatocyte nuclear factor 4 alpha) is one of the master regulators of pancreatic beta-cell development and function, and mutations in the HNF4 alpha gene are well-known monogenic causes of diabetes. As a member of the nuclear receptor family, HNF4 alpha exerts its gene regulatory function through various molecular interactions; however, there is a paucity of knowledge of the different functional complexes in which HNF4 alpha participates. Here, to find HNF4 alpha-binding proteins in pancreatic beta-cells, we used yeast two-hybrid screening, a mammalian two-hybrid assay, and glutathione S-transferase pulldown approaches, which identified EBP1 (ErbB3-binding protein 1) as a factor that binds HNF4 alpha in a LXXLL motif-mediated manner. In the beta-cells, EBP1 suppressed the expression of HNF4 alpha target genes that are implicated in insulin secretion, which is impaired in HNF4 alpha mutation-driven diabetes. The crystal structure of the HNF4 alpha ligand-binding domain in complex with a peptide harboring the EBP1 LXXLL motif at 3.15 angstrom resolution hinted at the molecular basis of the repression. The details of the structure suggested that EBP1's LXXLL motif competes with HNF4 alpha coactivators for the same binding pocket and thereby prevents recruitment of additional transcriptional coactivators. These findings provide further evidence that EBP1 plays multiple cellular roles and is involved in nuclear receptor-mediated gene regulation. Selective disruption of the HNF4 alpha-EBP1 interaction or tissue-specific EBP1 inactivation can enhance HNF4 alpha activities and thereby improve insulin secretion in beta-cells, potentially representing a new strategy for managing diabetes and related metabolic disorders.